Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Urinary Bladder Neoplasms 8Glioblastoma 3Squamous Cell Carcinoma of Head and Neck 2Melanoma 2Brain Neoplasms 2Urothelial Carcinoma of the Bladder 1Sarcoma 1Oligodendroglioma 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Nasopharyngeal Carcinoma 1Muscle-invasive Urothelial Cancer of the Bladder 1Mouth Neoplasms 1Lymphoma, Follicular 1Laryngeal Neoplasms 1Glioma 1Giant Cell Tumor of Bone 1Ganglioneuroblastoma 1Estrogen Receptor Positive Breast Cancer 1Craniopharyngioma 1Carcinoma 1Astrocytoma 1Alzheimer Disease 1

Interventions

Magnetic Resonance Spectroscopy 18pembrolizumab 16Specimen Handling 15Cisplatin 14Carboplatin 9Platinum 8Cetuximab 81,2-diaminocyclohexaneplatinum II citrate 8Radiotherapy, Intensity-Modulated 7Radiation 7Paclitaxel 7Biopsy 7Taxes 6Radiotherapy 6cemiplimab 4X-Rays 4Standard of Care 4Nivolumab 4Drug Therapy 4(225)Ac-DOTA-c(RGDyK) 4durvalumab 3Ultrasonography 3Surgical Procedures, Operative 3Sentinel Lymph Node Biopsy 3Observation 3Immunoglobulin G 3Disulfides 3ipatasertib 2Watchful Waiting 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mouth Neoplasms × Transurethral Resection of Bladder × 1 year × Clear all
NCT06980038 2026-06-01

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
44 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Laryngeal Neoplasms, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡